Literature DB >> 18494794

MuSK-positive myasthenia gravis is rare in the Polish population.

A Kostera-Pruszczyk1, A Kamińska, M Dutkiewicz, B Emeryk-Szajewska, M H Strugalska-Cynowska, A Vincent, H Kwieciński.   

Abstract

BACKGROUND AND
PURPOSE: MuSK-positive myasthenia gravis (MG) is diagnosed in 0-48% of cases with generalized seronegative MG in different populations. The presence of anti-MuSK antibodies generally relates to a severe course and lack of response to thymectomy. We analyzed for the first time the serology and clinical characteristics of MuSK-positive MG in the Polish population.
METHODS: One hundred and fifty-one patients were tested for the presence of anti-AChR and anti-MuSK antibodies: 62 with seronegative MG, including 14 with ocular seronegative MG, 48 age-matched patients with seropositive MG and 41 controls.
RESULTS: All patients with seropositive MG and the disease controls were MuSK-negative. Anti-MuSK antibodies were detected only in four patients with seronegative MG (8.7% of generalized seronegative cases): three women and one man. All four had predominantly bulbar involvement, and underwent thymectomy, with no apparent benefit. All of them improved clinically after immunosuppressive treatment with remissions lasting up to 7 years.
CONCLUSION: MuSK-positive MG is rare in Polish population accounting for only 8.7% of seronegative cases with generalized MG. This is consistent with emerging evidence for lower MuSK antibodies at more northerly latitudes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18494794     DOI: 10.1111/j.1468-1331.2008.02176.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  8 in total

Review 1.  Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.

Authors:  Michael H Rivner; Mamatha Pasnoor; Mazen M Dimachkie; Richard J Barohn; Lin Mei
Journal:  Neurol Clin       Date:  2018-05       Impact factor: 3.806

2.  Juvenile seropositive myasthenia gravis with anti-MuSK antibody after thymectomy.

Authors:  Anna Kostera-Pruszczyk; Hubert Kwiecinski
Journal:  J Neurol       Date:  2009-06-23       Impact factor: 4.849

3.  Clinical Features and Diagnostic Usefulness of Antibodies to Clustered Acetylcholine Receptors in the Diagnosis of Seronegative Myasthenia Gravis.

Authors:  Pedro M Rodríguez Cruz; Michal Al-Hajjar; Saif Huda; Leslie Jacobson; Mark Woodhall; Sandeep Jayawant; Camilla Buckley; David Hilton-Jones; David Beeson; Angela Vincent; Maria Isabel Leite; Jacqueline Palace
Journal:  JAMA Neurol       Date:  2015-06       Impact factor: 18.302

4.  Fatigue in myasthenia gravis: risk factors and impact on quality of life.

Authors:  Sarah Hoffmann; Johanna Ramm; Ulrike Grittner; Siegfried Kohler; Jana Siedler; Andreas Meisel
Journal:  Brain Behav       Date:  2016-08-02       Impact factor: 2.708

Review 5.  Overview of Dual-Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers.

Authors:  Przemysław Koźmiński; Paweł Krzysztof Halik; Raphael Chesori; Ewa Gniazdowska
Journal:  Int J Mol Sci       Date:  2020-05-14       Impact factor: 5.923

Review 6.  Myasthenia Gravis: Autoantibody Specificities and Their Role in MG Management.

Authors:  Konstantinos Lazaridis; Socrates J Tzartos
Journal:  Front Neurol       Date:  2020-11-30       Impact factor: 4.003

7.  Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status.

Authors:  Shin Joong Oh
Journal:  J Clin Neurol       Date:  2009-06-30       Impact factor: 3.077

Review 8.  Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics.

Authors:  Konstantinos Lazaridis; Socrates J Tzartos
Journal:  Front Immunol       Date:  2020-02-14       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.